Welcome to our dedicated page for Zentek Ltd. news (Ticker: $ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek Ltd. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zentek Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zentek Ltd.'s position in the market.
Zentek completed a case study on HVAC Total Cost of Ownership Savings for the City of Toronto, showcasing the benefits of using MERV 9A filters over MERV 13 filters. The study revealed annual cost savings of over $40 million, reduced carbon emissions, waste, and energy consumption. Zentek aims to provide property managers with a cost-effective, environmentally friendly solution to control infectious aerosols and keep people safe.
Zentek announces that its subsidiary, Triera Biosciences , has achieved positive results against avian influenza (H5N1) using multivalent aptamer technology. The development of a prophylaxis and therapeutic for highly pathogenic avian influenza has been prioritized, with promising initial test results. The binding affinity of the influenza aptamer is superior to that of the aptamer used for SARS-CoV-2, showing improved protection in animal models. The World Health Organization has labeled the current H5N1 outbreak as an 'enormous concern,' prompting governments worldwide to focus on combating the virus. Triera has filed a provisional patent on the influenza virus-targeting aptamer, aiming to develop assets to prevent further transmission of H5N1 and other infectious diseases.
Zentek announces board and management changes with the resignation of Dr. Francis Dubé as COO and Brian Bosse as a director, who has been appointed to the advisory board. The Company granted Mr. Bosse stock options for 40,000 shares at $1.42 per share.